# Pulmonology Referral

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: John Locke (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-EN001-SYN-TD
- Date: 1692-03-12
- Fictional facility: St. Posthumous Health Center
- Fictional author: Prudence Hartwell-Osei, MD
- Calendar frame: true historical dates (modern content is anachronistic)

> True-date frame: synthetic events are moved into the patient's historical lifetime. Codes, instruments, and treatments remain modern and are anachronistic.

- To: Ambrose Nwankwo-Fairfax, MD, Pulmonology
- Urgency: Routine, within two to three weeks; he is not in distress and has a reliever

## Referral question

A 59-year-old never-smoker with a cough since his late thirties and wheeze and breathlessness, worse every winter, in city air, and by open coal and wood fires at home. Please confirm the diagnosis (asthma, COPD from non-tobacco exposures, or both), advise on CT, and recommend treatment and pulmonary rehabilitation. **S**

## Questions for the consultant

1. Does he have asthma, COPD from non-tobacco exposures, or features of both, and how should the airflow limitation be interpreted?
2. Is a CT of the chest indicated, and what does it show?
3. What treatment do you recommend?
4. Should he have pulmonary rehabilitation?
5. How much do outdoor air pollution and indoor solid-fuel smoke contribute, and what exposure reduction do you advise?
6. What monitoring and follow-up do you advise?

## Pertinent history

Mr. Locke is a 59-year-old philosopher and author, trained in medicine, who has never smoked. He has coughed since his late thirties, worse each winter and within a day of any stay in the city, and better in warm weather and country air. For a year he has lodged in a country house where he reads most evenings by an open fire of coal and wood; before that he lived about 30 years in a large city near main roads. This winter he has had night cough two or three times a week, wheeze, and breathlessness after one flight of stairs, and after a recent city trip he could hardly breathe. No hemoptysis, fever, night sweats, weight loss, orthopnea, ankle swelling, reflux, or rhinitis. His father and brother died of consumption, by family account. Asthma Control Test 12; weight 62.0 kg, height 178 cm; oxygen saturation 95 percent; prolonged expiration with scattered wheeze; no clubbing or crackles. Chest X-ray today shows mild hyperinflation only. I have started albuterol as needed, asked him to stop using the open fires, and ordered a blood count with eosinophils, IgE, alpha-1 antitrypsin, NT-proBNP, and an interferon-gamma release assay. Full lung function tests with bronchodilator response, FeNO, and DLCO are booked at your laboratory on the day of your visit. **S**

- John Locke was born on 29 August 1632 (Julian; 8 September 1632, Gregorian) at Wrington, Somerset, to Puritan parents of modest means. His father, John Locke (1606 to 1661), was a country attorney who served in a cavalry company on the Parliamentary side early in the Civil War; his mother was Agnes Keene. He had one brother, Thomas, born in 1637. **D**
- He was educated at Westminster School and at Christ Church, Oxford, where he was elected to a studentship in 1652 and took his BA in 1656. **D**
- His father died on 13 February 1660/1 (Julian), at about 54, of consumption or some kindred malady, by his biographer's account; his only brother, Thomas, died of consumption soon afterwards, at about 26, leaving no children. **D**
- He studied medicine at Oxford and took the degree of Bachelor of Medicine in February 1674/5, with a licence to practise, but never took the doctorate. From 1667 he lived in the household of Lord Ashley (later the first Earl of Shaftesbury) as his physician, and in June 1668 he organized the surgical drainage of a large abscess above Ashley's liver, with advice from leading physicians including Thomas Sydenham. **D**
- From about 1667 he was a close friend of the physician Thomas Sydenham, accompanied him on visits to patients, helped him with his writings, and was praised by him; Sydenham embraced careful observation of disease. **D**
- His biographer H. R. Fox Bourne wrote that about 1670 Locke began to have a cough that seriously troubled him through the remainder of his life, and that an undated fragment in his hand from those years, titled 'Tussis', was the start of a paper on coughs. His health was already weak by the early 1670s; a letter from Sydenham, probably at the end of 1674, advised him to go to bed early and be very temperate and cautious, and from late 1675 to 1677 he lived in France, mostly at Montpellier, then much visited by invalids. **D**
- Lady Masham later wrote that although his travels in France had done his health some good, after his return he was still less able than before to stay long in London without retreating to a neighbouring village 'to recover the prejudice his health received from the smoke of that vast quantity of sea-coal which is burnt in this great city'. From then on he left London as often as he could, and always in the winter months. **D**
- Among his medical papers, an account of consumption that Fox Bourne describes as drawn from Sydenham's observation and confirmed by Locke attributes the frequency of consumptions in London to 'a perpetual mist' mixed with the fumes of the city's trades, 'but especially the sulphur and fumes of sea coals, with which the air is repleted; and these being sucked into our lungs ... give an occasion to a cough'. **D**
- He left England in the autumn of 1683, when he was under suspicion for his association with Shaftesbury, lived in Holland, and landed at Greenwich on 12 February 1688/9 (Julian). He soon declined a diplomatic mission on the ground of insufficient health, and wrote in April 1689 that he hoped to breathe more easily and be less troubled by his cough. **D**
- He found the smoke of London unfavourable to his health, and from the spring of 1691 lived at Oates, in the parish of High Laver, Essex, the home of Sir Francis and Lady Masham (Damaris Cudworth). **D**
- On 29 February 1691/2 (Julian; 10 March 1692, Gregorian) he wrote to Philipp van Limborch that since visiting Robert Boyle on his deathbed in December, 'my health has kept me in the country, for I found my lungs could not bear the smoke of the city'. **D**

8 later historical claims are omitted because they describe events after the index age. See the teaching note.

Baseline: Asthma Control Test: 12; PHQ-2: 1; Hemoglobin: 14.8 g/dL; White blood cells: 7.4 10*3/uL; Blood eosinophils: 0.46 10*3/uL; Platelets: 251 10*3/uL; Total IgE: 186 [IU]/mL (high); Alpha-1 antitrypsin: 131 mg/dL; NT-proBNP: 58 pg/mL; Interferon-gamma release assay (TB1 antigen minus nil): 0.02 [IU]/mL. All results are synthetic.

BP 122/74 mmHg; pulse 84 bpm; respirations 18/min; temperature 36.6 °C; oxygen saturation 95% on room air; weight 62 kg; BMI 19.6 kg/m². All vital signs are synthetic.

## Current medications

- Albuterol 90 mcg/actuation inhaler, two puffs every 4 hours as needed while tests are done; hold for 6 hours before spirometry **S**

## Plan so far

- Diagnostic workup: spirometry before and after bronchodilator, FeNO, DLCO, blood count with eosinophils, total IgE, alpha-1 antitrypsin, NT-proBNP, interferon-gamma release assay, chest X-ray, and CT of the chest if airflow limitation persists after bronchodilator; albuterol withheld for 6 hours before testing. Guideline: CMID: Clinical Monitoring Intelligence Database, asthma and COPD monographs (2026); Global Strategy for Asthma Management and Prevention, 2025 update (2025); 2020 Focused Updates to the Asthma Management Guidelines: A Report from the National Asthma Education and Prevention Program Coordinating Committee Expert Panel Working Group (2020); Global Strategy for the Prevention, Diagnosis and Management of COPD: 2025 Report (2025); Stanojevic S, et al. ERS/ATS technical standard on interpretive strategies for routine lung function tests. Eur Respir J 2022;60(1):2101499 (PMID 34949706) (2022); Bhakta NR, et al. Race and Ethnicity in Pulmonary Function Test Interpretation: An Official American Thoracic Society Statement. Am J Respir Crit Care Med 2023;207(8):978-995 (PMID 36973004) (2023) **S**
- Exposure reduction from today: no open coal or wood fires in his rooms (electric or heat-pump heating instead); a portable HEPA air cleaner sized for his study and bedroom; daily check of the air quality index, with city trips and outdoor exertion avoided on alert days; a well-fitted N95 respirator on unavoidable high-pollution days; quieter routes away from main roads. Guideline: CMID: Clinical Monitoring Intelligence Database, asthma and COPD monographs (2026); Global Strategy for Asthma Management and Prevention, 2025 update (2025); 2020 Focused Updates to the Asthma Management Guidelines: A Report from the National Asthma Education and Prevention Program Coordinating Committee Expert Panel Working Group (2020); WHO global air quality guidelines: particulate matter (PM2.5 and PM10), ozone, nitrogen dioxide, sulfur dioxide and carbon monoxide (2021); Carlsten C, et al. Personal strategies to minimise effects of air pollution on respiratory health: advice for providers, patients and the public. Eur Respir J 2020;55(6):1902056 (PMID 32241830) (2020); AQI Basics (2026); Air Cleaners and Air Filters in the Home (2026) **S**
- Vaccinations: pneumococcal conjugate vaccine PCV20 at the diagnosis visit; influenza, COVID-19, and RSV vaccines in the autumn; recombinant zoster vaccine. Guideline: CMID: Clinical Monitoring Intelligence Database, asthma and COPD monographs (2026); Adult Immunization Schedule by Age (2026) **S**
- Monitoring: Asthma Control Test, inhaler technique, adherence, reliever use, and exposures at every visit; spirometry and FeNO 3 months after starting treatment, then every 1 to 2 years; home peak flow diary. Guideline: CMID: Clinical Monitoring Intelligence Database, asthma and COPD monographs (2026); Global Strategy for Asthma Management and Prevention, 2025 update (2025); 2020 Focused Updates to the Asthma Management Guidelines: A Report from the National Asthma Education and Prevention Program Coordinating Committee Expert Panel Working Group (2020) **S**
